- Home
- EPSN vs PBYI Comparison
EPSN vs PBYI Comparison
Compare EPSN & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPSN
- PBYI
- Stock Information
- Founded
- EPSN 2005
- PBYI 2010
- Country
- EPSN Canada
- PBYI United States
- Employees
- EPSN N/A
- PBYI N/A
- Industry
- EPSN Oil & Gas Production
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- EPSN Energy
- PBYI Health Care
- Exchange
- EPSN Nasdaq
- PBYI Nasdaq
- Market Cap
- EPSN 155.9M
- PBYI 167.3M
- IPO Year
- EPSN N/A
- PBYI N/A
- Fundamental
- Price
- EPSN $7.68
- PBYI $3.31
- Analyst Decision
- EPSN Strong Buy
- PBYI Strong Buy
- Analyst Count
- EPSN 1
- PBYI 1
- Target Price
- EPSN $7.00
- PBYI $7.00
- AVG Volume (30 Days)
- EPSN 237.1K
- PBYI 354.2K
- Earning Date
- EPSN 08-12-2025
- PBYI 07-31-2025
- Dividend Yield
- EPSN 3.24%
- PBYI N/A
- EPS Growth
- EPSN N/A
- PBYI 143.51
- EPS
- EPSN 0.20
- PBYI 0.77
- Revenue
- EPSN $39,699,172.00
- PBYI $232,709,000.00
- Revenue This Year
- EPSN $41.35
- PBYI N/A
- Revenue Next Year
- EPSN N/A
- PBYI N/A
- P/E Ratio
- EPSN $39.60
- PBYI $4.34
- Revenue Growth
- EPSN 35.21
- PBYI 2.68
- 52 Week Low
- EPSN $4.95
- PBYI $2.23
- 52 Week High
- EPSN $8.50
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- EPSN 50.93
- PBYI 47.57
- Support Level
- EPSN $6.95
- PBYI $3.34
- Resistance Level
- EPSN $8.50
- PBYI $3.39
- Average True Range (ATR)
- EPSN 0.26
- PBYI 0.16
- MACD
- EPSN -0.02
- PBYI -0.04
- Stochastic Oscillator
- EPSN 47.10
- PBYI 19.05
About EPSN Epsilon Energy Ltd. Common Share
Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.